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Abstract
Background: Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), infects ~8 million annually
culminating in ~2 million deaths. Moreover, about one third of the population is latently infected, 10% of which
develop disease during lifetime. Current approved prophylactic TB vaccines (BCG and derivatives thereof) are of
variable efficiency in adult protection against pulmonary TB (0%–80%), and directed essentially against early phase
infection.
Methods: A genome-scale dataset was constructed by analyzing published data of: (1) global gene expression
studies under conditions which simulate intra-macrophage stress, dormancy, persistence and/or reactivation; (2)
cellular and humoral immunity, and vaccine potential. This information was compiled along with revised
annotation/bioinformatic characterization of selected gene products and in silico mapping of T-cell epitopes.
Protocols for scoring, ranking and prioritization of the antigens were developed and applied.
Results: Cross-matching of literature and in silico-derived data, in conjunction with the prioritization scheme and
biological rationale, allowed for selection of 189 putative vaccine candidates from the entire genome. Within the
189 set, the relative distribution of antigens in 3 functional categories differs significantly from their distribution
in the whole genome, with reduction in the Conserved hypothetical category (due to improved annotation) and
enrichment in Lipid and in Virulence categories. Other prominent representatives in the 189 set are the PE/PPE
proteins; iron sequestration, nitroreductases and proteases, all within the Intermediary metabolism and
respiration category; ESX secretion systems, resuscitation promoting factors and lipoproteins, all within the Cell
wall category. Application of a ranking scheme based on qualitative and quantitative scores, resulted in a list of 45
best-scoring antigens, of which: 74% belong to the dormancy/reactivation/resuscitation classes; 30% belong to the
Cell wall category; 13% are classical vaccine candidates; 9% are categorized Conserved hypotheticals, all
potentially very potent T-cell antigens.
Conclusion: The comprehensive literature and in silico-based analyses allowed for the selection of a repertoire
of 189 vaccine candidates, out of the whole-genome 3989 ORF products. This repertoire, which was ranked to
generate a list of 45 top-hits antigens, is a platform for selection of genes covering all stages of M. tuberculosis
infection, to be incorporated in rBCG or subunit-based vaccines.
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Background
Mycobacterium tuberculosis (Mtb), the causative agent of
tuberculosis (TB), remains a major health threat. Each
year, 8 million new TB cases occur and 2 million individ-
uals die of TB [1]. Moreover, it is estimated that one third
of the population is latently infected with Mtb, of which
~10% will develop active disease during lifetime. The
development of active TB occurs when the balance
between natural immunity and the pathogen changes
(e.g. upon waning of protective immune response during
adolescence and in HIV patients, [2]). In addition, at
present ~50 million individuals are probably infected
with multi drug-resistance (MDR) strains of Mtb (WHO,
2006), rendering antibiotic treatment difficult.
The current vaccine, introduced over 80 years ago, is the
live attenuated bacterium Mycobacterium bovis Bacillus
Calmette-Geurin (BCG), designed as a prophylactic vac-
cine for pre-infection administration. BCG is known to
protect young children against severe forms of TB however
it does not efficiently and consistently protect adults
against the most prevalent form of the disease, namely,
pulmonary TB (variable protective efficacy ranges from
0% to 80%), nor does BCG offer protection from estab-
lishment of latent TB and subsequent reactivation [3-9].
In principle, current putative vaccination strategies against
TB can be divided into two groups: (a) prophylactic vac-
cines (aimed at disease prevention), based on BCG with
or without antigens secreted by replicating bacteria recog-
nized during the early stage of infection (e.g. ESAT-6 or
Ag85A/B), or protective mutants (live attenuated BCG
substitutes) and (b) as yet undefined post-exposure vac-
cines (boosting BCG) aimed at elimination/containment
of latent TB and prevention of reactivation. Ideally, a
prime-boost approach comprising of a prophylactic vac-
cine with subunit, viral vectored or DNA-based vaccines,
based on late-stage antigens induced in the dormant stage
(transition from replicating to non-replicating stage,
latency antigens) or resuscitation/reactivation stage,
should have maximum impact on all stages of Mtb infec-
tion [2,6,10-15].
In the past few years there have been important break-
throughs in the development of improved prophylactic
TB vaccines. Novel vaccine candidates, mostly selected as
single gene products, include: rBCG vaccines (e.g. rBCG30
– expressing Ag85B or ΔureCHly+rBCG – an urease defi-
cient strain expressing listeriolysin), virus-based recom-
binant vaccines (e.g. MVA85A – Rv3804c expressed in
replication-deficient vaccinia virus), live attenuated Mtb
strains and subunit vaccines comprising of dominant
secreted antigens which could boost the immune
response after priming with BCG (e.g. Mtb72F, Ag85B-
ESAT-6 fusion), (reviewed by [1,4-7,10,16]).
Post-exposure vaccine development requires identifica-
tion of gene products participating in adaptation of Mtb
to the intracellular habitat as Mtb changes from replica-
tion to dormancy or from dormancy to resuscitation.
Moreover, in the absence of effective prediction models
and animal models assessing protective immunity, evalu-
ation of a large number of individual antigens remains
laborious [12]. In vitro gene expression studies under con-
ditions which mimic dormancy and/or reactivation con-
stitute the major source of information. Availability of
whole genome sequences of diverse mycobacterial strains
in conjunction with data from global analyses such as
whole-genome DNA microarray and proteomic technolo-
gies have been the subject of intensive research in the
recent years, both at site of pulmonary TB and in ex vivo
macrophages [11,17]. To identify genes expressed specifi-
cally during latency, different in vitro conditions have
been suggested to model the harsh environment within
macrophages or granulomas. These include oxygen depri-
vation, nutrient starvation and iron limitation. Together
with expression studies in lungs/granulomas, in phagocy-
tized bacteria inside activated macrophages or in murine/
guinea pig infection models, these datasets provide better
understanding of the transition of bacteria through stages
of active multiplication, dormancy and resuscitation.
Based on bioinformatic studies and analysis of multiple
dormancy-related datasets, novel drug targets against the
dormant phase of Mtb infection have been recently iden-
tified [18].
Several attempts have been made to modify the immuno-
genicity or antigenicity of BCG by generating recombinant
strains expressing cytokines, pore-forming listeriolysin/
perfringolysin, immunodominant antigens or additional
antigens missing from the genome of the avirulent M.
bovis BCG genome. Over 200 genes located in 14 gene seg-
ments assigned to defined regions of difference (RDs) are
missing in the vaccine strain. In principle, potency of BCG
vaccines could be improved by supplementing with miss-
ing immunodominant RD genes; however critical evalua-
tion is required since RD regions are associated with
virulence. Indeed, when BCG was supplemented by the
classical RD-1 antigen ESAT-6 (with or without Ag85B
[19]), enhanced protection was observed in mice however
the recombinant strain was more virulent as compared to
the wild-type. In a more recent study, Kalra & Grover [20]
demonstrated the enhanced prophylactic potential of
selected combinations of RD antigens supplementing
BCG, improving protection in aerosol exposed mice.
Mtb is an intracellular pathogen and as such cell mediated
immunity rather than antibody-mediated immunity is
essential for the control of bacterial replication and subse-
quent protection against TB [7]. It is thought that a coor-
dinated response of the cellular immune response isBMC Medical Genomics 2008, 1:18 http://www.biomedcentral.com/1755-8794/1/18
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fundamental to the protective immunity [21-23], includ-
ing both CD4 and CD8 T-cells and several cytokines such
as IFNγ and TNFα. It has been suggested that CD4 T-cells
are mainly crucial during the early phases of infection,
while the CD8 T-cells play an important role in the
chronic phase of the disease [21-23], however little is
known about antigen-specific human T-cell responses
against persisting mycobacteria, particularly in the context
of latent infection and protection against disease, with the
exception of some products of the DosR regulon [24,25].
Therefore, rational selection of sequences that may func-
tion as T-cell epitopes in vaccine formulations is crucial.
Relatively few human CD8 T-cell epitopes have been
found by conventional methods. The availability of the
genomic sequence [26] provides new horizons in analyz-
ing the potential immunome of the bacilli, using in silico
identification of CTL binders. Several prediction screens
of Mtb T-cell epitopes were reported to date [25,27-32],
nevertheless these analyses were mostly restricted either to
few MHC alleles or to a limited number of preselected
subset of genes.
In this study, we have combined multiple published data-
sets from: (a) gene expression and DNA microarray exper-
iments mimicking conditions leading to dormancy or at
the dormant state; (b) genome-wide insertional mutagen-
esis examining gene essentiality under different condi-
tions; (c) genes expressed in macrophages under
conditions mimicking persistence; (d) genes expressed in
lungs/granulomas; (e) expression under iron limiting
conditions; (f) identification of genes products reported
to elicit humoral and cellular response or potential vac-
cine candidates; (g) in silico identification of T-cell
epitopes by dedicated epitope-mapping algorithms and
databases compiling relevant experimental data. We
designed a whole-genome scoring, ranking and prioritiza-
tion algorithm and used it to analyze the combined data-
set. Accordingly, we selected a set of 189 putative vaccine
candidate proteins covering all disease phases, from
which we further derived a shorter list of 45 top-ranking
antigens for vaccine studies.
Methods
Genome sequences and annotations of Mycobacterium
tuberculosis  H37Rv [GenBank: AL123456] were down-
loaded from the NCBI [33]. Sequence similarity searches
were conducted using the Blast algorithm, vs. the non-
redundant (nr, NCBI) database. Comparisons against sec-
ondary databases of domains and motifs were performed
as follows: CDD [34], SMART [35], Pfam [36], Interpro
[37], Prosite [38]. Secretion signals were analyzed by Sig-
nalP [39,40] for the secretion via the SecA pathway, and
TATfind for searching of the Twin-Arginine Translocation
(Tat) motif of the TAT pathway [41]. Transmembrane hel-
ical segments were predicted by Tmpred [42]. The data-
base of bacterial lipoproteins, Dolop [43] was searched
for putative lipoproteins. Predictions of CTL epitopes
were carried out using the NetCTL integrative approach
[44], which combines predictions of MHC class I binding,
TAP transport efficiency, and proteasomal cleavage. The
analysis was conducted for each of 12 HLA supertypes. A
threshold of 1.25 was set on the combined prediction
score. The results were parsed by in-house perl scripts.
Immune epitope information was complemented by que-
rying the IEDB database [45] for documented B- and T-cell
epitopes. The following Mtb-related servers and databases
were screened for additive relevant data: TB-sgc – The TB
Structural Genomics Consortium [46], Tuberculist-the
database on Mycobacterium tuberculosis genetics [47],
TBDB – an integrated platform for TB drug discovery [48],
MTBreg – The Database of Conditionally Regulated Pro-
teins in Mycobacterium tuberculosis [49] and BioHealthBase
– the Biodefense and Public Health Database [50]. Func-
tional categories provided for the selected ORF products
were as implemented in [26,51], and their assignment to
each of the antigen was derived from the Tuberculist data-
base (see above). Classes/phases of Mtb infection were
assigned as well to the selected antigens: the well estab-
lished classical antigens, DosR-regulated antigens (as
reported in [52,53]), reactivation antigens (antigens listed
by Talaat and his coworkers [54], as well as documented
putative implications of individual antigens), and the 5
known resuscitation antigens [55]; antigens not belong-
ing to any of the above classes, were denoted as "Others".
p-values were calculated using the binomical distribution
of frequencies.
Results and Discussion
The strategy for whole genome-based selection of candi-
date genes to be included in a vaccine platform, consisted
of: (1) compilation of documented data originating from
global analyses pertaining to criteria relevant to vaccine
and to M. tuberculosis (Mtb) pathogenesis (2) selection of
a subset of genes for further evaluation, based on the accu-
mulated data, by cross matching the data in the different
criteria; (3) bioinformatic analyses aimed at both further
characterization of the candidate genes, in terms of anno-
tation, gene context and cellular localization and; immu-
noinformatic analysis conducted for the prediction of T-
cell epitopes; (4) development and application of a rank-
ing scheme, based on qualitative and quantitative meas-
ures, as a tool for prioritizing the selected candidates. A
schematic presentation of the various steps, as well as the
reductive scheme generating a list of best-hit antigens, is
given in Figure 1.
Generation of a comprehensive, literature-based dataset
The first step towards the selection of vaccine candidates
consisted of accumulating published experimental data,
by an extensive literature scan of documented analyses,BMC Medical Genomics 2008, 1:18 http://www.biomedcentral.com/1755-8794/1/18
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with emphasize on global analyses. Target genes to be
involved in a future vaccine are either ORF products
which have the potential to elicit an immune response
(humoral and/or cellular), and/or involved in various
manifestations and phases of the infection and/or viru-
lence (as a basis for an attenuated strain). Accordingly, we
assembled all evidences into the following general 11 cat-
egories (Table 1):
Macrophages
Numerous comprehensive studies related to the infection
of the macrophages by the bacilli were conducted, aiming
at identifying the genes involved in processes as adhesion
to the host cell, phagocytosis-mediated entry and survival
in the macrophage, adaptation to the environment and
resistance to both phagocytosis and lysis, and to free rad-
icals. Different approaches were applied to characterize
both the profile of expression at various relevant condi-
tions and the growth/survival of wild-type Mtb and
selected mutants. These include subtractive hybridization,
transcriptomics, proteomics and mutagenesis. In our
screen, we included representative studies covering the
abovementioned aspects, as detailed in Table 1[56-64].
MprAB
This two component system is one of two major families
of transcriptional regulators necessary for stress adaption
processes. The system is induced in response to various
stress conditions and was shown to be required for growth
in vivo during the persistent stage of infection. Compara-
tive DNA microarray analysis of Mtb H37Rv and an mprA
mutant strain enabled to profile the gene expression in
each of the strains and to identify 221 genes which were
presumably regulated by MprA under stress conditions
[65].
Flowchart of the selection procedure – data mining and bioinformatic analyses Figure 1
Flowchart of the selection procedure – data mining and bioinformatic analyses. A schematic presentation of the 
reductive approach applied for the whole-genome selection of Mtb vaccine candidates.
344 ORF products 344 ORF products
189 ORF products 189 ORF products
45 top 45 top- -ranking candidates ranking candidates
Step I:
•Generation of a comprehensive, global analyses 
literature-based dataset according to 11 categories
•Cross matching all data for 1209 ORF products having 
at least one documented evidence
•Selection of 344 ORF products having >2 evidences of  
significant value or multiple evidences with below-
threshold value
Step II:   
•Assignment of a preliminary total score based on the # 
of evidences in the various categories
• Choosing highly scored  143 antigens (score≥3)
•Appending 46 of the 201 low-scoring hits (preliminary 
total score <3) having vaccine potential or relevance to 
virulence
Step III:   
•Assigning  each ORF product a qualitative score 
according to 14 criteria
•Assigning each ORF product a  quantitative score 
according to a numerical scheme
•Ranking of the antigens based on qualitative and 
quantitative scores.
3989 ORF products 3989 ORF products
Mycobacterium  tuberculosis 
H37Rv
• Literature scan of 
documented global analyses 
• Sequence similarity searches
• Domain and motifs analyses
• Cellular localization
• Searching of MTB-related 
databases
• Immunoinformatics prediction 
of CTL epitopes
In silico analysis
• Manual curation/revision of 
literature on specific antigens BMC Medical Genomics 2008, 1:18 http://www.biomedcentral.com/1755-8794/1/18
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Table 1: Information sources for the knowledge dataset used in this study.
(I) Literature-derived evidences:
Category Reference Experimental model/method
Macrophages Growth/Survival Sassetti et al., 2003 Genes essential for growth (in strains H37Rv & BCG) (TraSH, microarray)
Rengarajan et al., 2005 Genes necessary for survival in macrophages (TraSH, microarray)
Stewart et al., 2005 Screening of mutants unable to inhibit phagosome acidification (STM, 
microarray analysis)
Rosas-Magallanes et al., 2007 Screening of mutants attenuated in human macrophages (STM)
Expression profile Monahan et al., 2001 M. bovis BCG protein expression in macrophages (human cell line), as 
compared to growth in culture media or conditions of heat shock (1,2-DE, 
proteomic analysis)
Fisher et al., 2002 Genes induced following in vitro acid shock (microarray, RT-PCR)
Schnappinger et al., 2003 Differential transcriptome of genes in the phagosome, in comparison to 
their expression in culture (microarray, RT-PCR)
Talaat et al., 2004 Comparison of H37Rv expression profile between growth in lungs of BALB/
c vs. macrophages (microarray, RT-PCR)
Cappelli et al., 2006 Comparison of H37Rv gene expression in human macrophages vs. synthetic 
medium (microarray, RT-PCR)
MprAB Regulation He et al., 2006 Genes upregulated by MprA (in SDS treated culture); (microarray RT-PCR)
Hypoxia Expression profile Voskuil et al., 2003 Expression profile at low O2 and low concentrations of NO (inhibitor of 
aerobic respiration); dormancy regulated gene set; mostly overlaps with 
Sherman; microarray
Sherman et al., 2001 H37Rv gene expression under hypoxia (from ambient to 0.2% O2 for 2 h)
Schnappinger et al., 2003 Analysis of mutants deficient in NO synthase
Reactivation Expression profile Talaat et al., 2007 Difference in expression in BALB/c vs. broth after incubation with 
dexamethasone (microarray)
Tufariello et al., 2006 Effect of rpf deletions on persistence and reactivation in mouse
Dormancy Expression profile Voskuil et al. 2003 Expression profile at low O2 and low concentrations of NO; dormancy 
regulated gene set; mostly overlaps with Sherman; microarray
Voskuil et al., 2004 Transcription profile in non-proliferating conditions; genes induced under 
oxygen-depleted conditions (nrp-non-replicating persistence)
Starck et al., 2004 Proteome comparison of aerobic and anerobic conditions (MTB Harlingen 
strain)
Lungs Expression profile Fenhalls et al., 2002 Expression of genes in human tuberculous granulomas (in situ hybridization)
Shi et al., 2003 Transcription pattern of 6 H37Rv genes in mouse lungs (RT-PCR)
Shi et al., 2004 Transcription pattern of H37Rv major secreted antigens in mouse lungs 
(RT-PCR)
Dubnau et al., 2005 Expression of genes during infection in mouse lungs vs. medium (promoter 
trap)
Rachman et al., 2006 Identification of genes expressed during pulmonary TB; transcription profile 
from clinical lung samples (granuloma vs. in vitro) (microarray)
Tufariello et al., 2006 rpf gene expression in the lungs of infected mice
Growth/Survival Lamichhane et al., 2005 Genes required for in vivo survival im mouse lungs (microarray screening of 
transposon mutants)
Jain et al., 2007 Mutants tested for lung implantation in survival in guinea pigs and mouse 
aerosol models
Acr Co-regulation Florczyk et al. 2003 Identification of a 18-bp palindromic sequence motif
Secreted Gomez et al., 2000 in silico identification of proteins harboring signal peptides but lacking 
membrane anchoring moieties.
Immunogeni
city
B-cell response Brusasca et al., 2001 Antibody response to 6 H37Rv RD1 proteins in guinea pigs and sera from 
pulmonary TB patients
Yeremeev et al., 2003 Elicitation of B-cell response in mice immunized with rpf proteins (H37Rv)
Weldingh et al., 2005 Seropotential of 35 proteins, tested by response with sera of TB patients
Amor et al., 2005 Seroreactivity of MTB specific proteins previously predicted as secreted
T-cell response Cockle et al., 2002 Immune response in cattle against 13 ORFs (RD1, RD2 and RD14 antigens).
Vekemans et al., 2004 Profile of immune response in healthy and TB patients against a series of 
mycobacterial antigens
Mustafa et al., 2006 Characterization of Th1 cell reactivity with RD1 antigens and peptides
Iron-
regulated
Regulation Rodriguez et al., 2002 Identification of genes induced by iron and by the iron-dependent regulator 
IdeR – comparison of H37Rv and ideR-mutant strains (microarray)BMC Medical Genomics 2008, 1:18 http://www.biomedcentral.com/1755-8794/1/18
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Hypoxia
One of the well established models of the tuberculi non-
replicating dormant state, is the Wayne model [66], which
is based on culturing Mycobacteria in decreasing concen-
trations of oxygen, mimicking the environment in which
the bacteria transform to a non-replicating form, residing
in granulomas, which are of hypoxic nature. In this
respect, growth under low O2 and NO concentration or
under depletion of NO synthase are the major conditions
implemented to identify the expression profile related to
hypoxic conditions. Sherman and his coworkers [67] used
a whole genome microarray to identify 101 genes whose
expression is significantly altered by hypoxic conditions,
of which 47 are induced. A similar approach was followed
by Voskuil and coworkers [52], resulting in a set of 48
genes affected by low O2 concentration or by the presence
of nontoxic concentration of NO (known to inhibit bacte-
rial respiration). Likewise, mutants deficient in NO syn-
thase were used to profile the genes expressed during
hypoxia-like conditions [62].
Reactivation
Very little is known about the genetic basis and the signals
which are involved in the reactivation from the dormant
state of the mycobacterium. In an attempt to decipher the
factors which govern the phase of reactivation, some
researchers adopted an immunossupressive model, in
which reactivation of latent infection occurs following
treatment with the immunossupressive reagent dexamet-
hazone [68,69]. Using this model, Talaat and coworkers
[54] recently identified a total of 174 genes that were up-
regulated during the reactivation phase of tuberculosis. A
family of 5 proteins, denoted resuscitation promoting fac-
tors (Rpfs), has been shown to be involved in regulating
mycobacterial growth [55,70]. Single deletions of the Rpf
members were used to determine the effect of these pro-
teins on the kinetics of reactivation [71].
Dormancy
The shifting to the non-replicating persistence state ("dor-
mancy") of the bacteria is accompanied by modulation of
expression of genes related to the adaptation to the non-
replicating conditions. The adaptive processes include:
starvation of essential nutrients, cessation of growth in
stationary phase, and depletion of oxygen. Of these, the
later is the most investigated and constitutes the basis for
the in vitro model used in dormancy studies. The set of
genes found to be induced by hypoxia, nitric oxide and
adaptation to the non-replicating conditions, under the
regulation of DosR (Dormancy survival regulator,
Rv3133c), were denoted as the dormancy/DosR regulon
[52,53]. Transcription profiles were determined by a
whole-genome comparative DNA microarray analysis of
the exponential growth at time points in the stationary
phase, as well as under specific non-replicating persistent
conditions of low oxygen and nitric oxide [52,53,62]. In a
Vaccine Immunization/
protection
Mollenkopf et al., 2004 DNA vaccine candidates preselected by comparative proteomics (present 
in MTB, absent from BCG) evaluated for their protective potential (aerosol 
challenge of H37Rv, mice)
Vipond et al., 2006 DNA vaccine candidates chosen by supporting data, such as virulence-
associated, level of expression, growth in various conditions etc. (aerosol 
challenge of H37Rv, guinea pigs)
Roupie et al., 2007 DNA vaccine candidates chosen from the DosR regulon (on the basis of 
strong T-cell responses in infected humans), evaluated for their 
immunogenicity potential (mice immunizations).
(II) in silico-based evidences:
Category Source of information/analyses
Cell wall Membranal and 
anchored
Assignment of ORF products as membrane-attached, by:
(1) Prediction of membrane-spanning regions by TMpred
(2) Inference from annotation and/or domain analysis
Repeats Inference from annotation and/or domain analysis
T-cell 
immunogeni
city
MHC class I and 
class II binders
Compilation of experimental and predicted data from:
(1) Screening of the public repository database of immune epitope data (IEDB)
(2) Particular experimental evidences from the literature
(3) Literature-derived predicted T-cell epitopes
(4) Prediction of CTL epitopes by an integrative approach (NetCTL)
Table 1: Information sources for the knowledge dataset used in this study. (Continued)BMC Medical Genomics 2008, 1:18 http://www.biomedcentral.com/1755-8794/1/18
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separate analysis, the differential expression of genes
under aerobic and anaerobic conditions was deciphered
by a proteome (2D-PAGE) analysis, revealing proteins
which were unique or more abundant in the anaerobic
conditions [72].
Lungs
As the first point of entry of the M. tuberculosis upon infec-
tion, following implantation the bacteria reside and repli-
cate in granulomas in the lungs. Various strategies were
employed to depict the pattern of expression both in
human granulomas and in guinea pig and mouse lungs,
and these revealed an extensive list of genes necessary for
growth and survival, as well as identification of genes
expressed during infection in the lungs (detailed in Table
1, [17,71,73-78]).
Acr-coregulated
The 16 kDa α-crystallin (Acr) protein was shown to be
induced and required inside macrophages and highly
expressed in the presence of NO, low O2 concentrations
and in the stationary phase ([79-81] and references
therein). The Acg gene product was later identified as a
novel macrophage-induced gene, whose expression is co-
regulated with that of acr [79]. Aiming at identifying other
genes which are under the same regulation, an acr-coregu-
lated gene (ACG) family was denoted, following the iden-
tification of a conserved sequence motif found in the
promoter region of the 15 family members [82].
Secreted
Proteins which are exported from the cytoplasm and
either secreted to the milieu or anchored to the cell wall,
are of a major importance as targets of the immune sys-
tem, in view of their exposure in the host. The secretion
pathways in M. tuberculosis are less established than in
other bacilli, in particular those implicated in virulence
factor secretion. In addition to the classical pathways (the
SecA and TAT systems), the pathogen harbors a unique
virulence-related secretion system – ESX system and prob-
ably additional systems which remain to be identified.
Identification of secreted proteins by a whole genome glo-
bal analysis was conducted by Gomez and coworkers [83].
A predictive approach of all proteins harboring a secretion
signal of the classical SecA pathway, but lacking mem-
brane spanning segments, was carried out, resulting in the
identification of 52 proteins, the location of which was
further confirmed by fusion to a marker of subcellular
localization.
Immunogenicity
Data on immune response was compiled from global
analyses covering both elicitation of humoral and cellular
responses following vaccination of model animals, as well
as seroreactivity profiles of selected antigens with sera
from healthy and TB patients (see Table 1 and data per-
taining to individual ORF products, in the text, [30,84-
89]).
Iron regulated
As for many other pathogens, Mycobacterium tuberculosis
infection is dependent on the availability of iron in the
depleted macrophage, and therefore iron sequestration
from the host is necessary for virulence [90,91]. Iron is
also known to influence both the innate and adaptive
immune responses to Mtb [92]. Failure to assemble the
iron acquisition machinery or to repress iron uptake has
deleterious effects for Mtb [90,91]. In addition to express-
ing iron-uptake systems during iron deficiency, Mtb dis-
plays several changes in gene expression in response to
iron availability. All changes taking place during the
response to iron deficiency are controlled by iron-depend-
ent regulatory networks. The IdeR gene product is a dual
functional regulator controlling transcription of genes
involved in iron acquisition, iron storage and macrophage
survival [93,94]. ideR is an essential gene in M. tuberculosis
and its deletion results in deregulated siderophore biosyn-
thesis and sensitivity to oxidative stress [94]. The tran-
scription profile of genes whose expression is modulated
by iron levels was mapped by a DNA microarray analysis,
and revealed 155 genes which were iron-regulated; one
third of these were regulated by IdeR [94].
Vaccine
Data pertaining to vaccine potential of the antigens was
derived from publications describing global analyses of
preselected antigens for their potential to induce an
immunoprotective response [25,95-97]. These include
mostly evaluation of DNA vaccine candidates, as listed in
Table 1. For this specific category, a large number of evi-
dence was also derived from information pertaining to
particular antigens studied both as DNA or protein vac-
cine candidates [14,20,24,25,71,84,98-141], among
which are obviously the well established classical anti-
gens.
Selection of a dataset of ~200 vaccine candidates
Of the total 3989 ORF products, 1209 had documented
evidence in at least one of the sources listed in Table 1.
Cross-matching of the compiled data for all 1209 ORF
products, allowed for a preliminary selection of 344 anti-
gens, for which either more than two values above the
threshold exist, or, alternatively, one value above the
threshold together with at least two other values with
lower values (below the threshold) were present. The
threshold for each literature source was set as the median
of the experimental values extracted from the particular
literature source.BMC Medical Genomics 2008, 1:18 http://www.biomedcentral.com/1755-8794/1/18
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The literature sources which were used to generate the
dataset (Table 1) were grouped within each category (e.g.
all 9 studies in the Macrophage category were treated as a
single piece of evidence). Following the threshold selec-
tion described above (step I in Figure 1), each ORF prod-
uct was assigned a "+" sign in a given category if
experimental data has been reported at least in one study.
Summation of the "+" signs across all categories, for each
ORF product, produced a total, un-weighted score, with a
maximal possible total score of 11 (according to the
number of categories). Among the 344 antigens, 143 had
a relatively high total score of 3–8. Of the remaining 201
low scoring antigens, 46 had documented information
related to vaccine potential and/or a critical role in the
pathogenesis traits of the bacilli. As such, these 46 anti-
gens were added to the 143 high scoring antigens (having
a total score ≥ 3), generating the final list of 189 candi-
dates for further evaluation (Additional file 1: List of 189
selected antigens).
Bioinformatics analysis of the 189 vaccine candidates
Inspection of the list of 189 candidates reveals that,
according to the annotation deposited at the NCBI, 69
antigens have no assigned function. In an attempt to fur-
ther characterize the candidate genes, we followed an in-
depth bioinformatic analysis which was aimed at revising
the existing annotation, as well as determining the cellular
localization and the presence of secretion signals, and
protein repeats patterns. The revised annotation was thus
based on sequence similarity searches against updated
databases, and domain/motif assignment following que-
rying secondary databases (see: Methods). Also, Mtb-
related servers were screened to extract function-related
information (see: Methods). Additive information was
derived from the accumulating data in the literature, and
specifically on functional characterization of particular
genes or their mycobacterial orthologs. These in silico
analyses and data mining resulted in the assignment of a
putative function to 60% of the 69 candidates with
unknown function, and the addition of further functional
details to 15 candidates (Additional file 1: List of 189
selected antigens).
Immunoinformatic analysis of the 189 vaccine candidates
As mentioned above, the significance of the cellular
immune response in protection against intracellular path-
ogens in general and Mtb in particular, is well docu-
mented. We therefore conducted a comprehensive
mapping of the T-cell immunity potential of the selected
antigens, by compiling both the results of an in-silico
search for putative T-cell epitopes and experimental pub-
lished data.
Using NetCTL as an integrative approach for prediction of
9-mer CTL epitopes [44], we analyzed the 189 proteins for
the presence of MHC binding peptides. The analysis was
conducted on 12 HLA supertypes, representing ~120
human MHC alleles and providing a population coverage
of 99.8% worldwide. For our large scale analysis, we have
chosen a relatively high combined score threshold of
1.25, which gives preferentiality to true binders. At this
threshold, the specificity is 0.993 and the sensitivity is
0.54 (as reported by the NetCTL server). Most potent can-
didates were considered as those having binders for as
many supertypes (this argument was further used to rank
the antigens at a later stage, see below). Compared to in
silico studies of the Mtb antigens immunomic potential
[25,27-29,31,32,125], the analysis described herein is
inclusive both with respect to its scope and to the number
of HLA alleles covered.
In addition to the theoretical analysis, experimental evi-
dences for T-cell epitopes were retrieved both from the
IEDB database [45], by querying each of the antigens as
well as data for cellular immunoreactivity of individual
gene products from the extensive study of Leyten et al.
[24] and other literature sources [24,25,84-
86,88,99,102,106,115,119,124,127,142-144]. The com-
piled T-cell immunity data was added as yet an additional
criterion for further evaluation and ranking of the 189
antigens, leading to a total of 14 criteria.
Assignment of a qualitative score to the 189 vaccine 
candidates
The compilation of the experimental data with the bioin-
formatic and immunoinformatic analyses, together with
biological reasoning resulted in a comprehensive knowl-
edge-based dataset of the 189 vaccine candidates (Addi-
tional file 2: "Raw data of the 189 selected antigens"),
according to a total of 14 criteria (Table 1). In order to
rank the list, and further prioritize the antigens, we devel-
oped a scheme which is based on both a qualitative and a
quantitative score calculated for each antigen. The scores
are calculated according to 14 criteria, encompassing the
11 literature-based categories as well as T-cell immunome
data, cell wall and repeats-derived information. The first
scoring iteration assigns an equal weight to each criterion.
A "+" sign is indicated for each indication in each of the
criteria, and an arithmetic score is calculated, by summing
the "+" signs (See Additional file 3: 'Qualitative scores for
189 selected antigens'). The scores obtained ranged
between 9-1, exhibiting a normal distribution of number
of antigens per scores, as follows: scores 9–8: 11.6%;
scores 7–6: 32.8%; scores 5–4: 45.5% and; scores 3-1:
12%. This rather naïve scoring is of value in rendering a
preliminary ranking, which allows to limit the bias that
may arise in favor of antigens with an extensive coverage
in the literature. Nevertheless, it suffers from some inher-
ent limitations: (1) as described above, an equal weight
was assigned to each criterion, yet their differential rele-BMC Medical Genomics 2008, 1:18 http://www.biomedcentral.com/1755-8794/1/18
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vance to vaccine development is not reflected; (2) any
data in a specific criterion contributed equally to the total
qualitative score, regardless of the relative potency of the
actual result reported in the publication from which the
data was extracted, or for data obtained from our analyses.
(3) in spite of a broad range of qualitative scores, their dis-
tributions reveal large clusters of genes. To note, groups of
17 and 19 genes harbor a qualitative score of 8 and 7,
respectively, while a group of 44 genes have a qualitative
score of 6. This implies that in order to prioritize the
equally-scored antigens within the groups, we had to fur-
ther refine our scoring system and apply additional meas-
ures.
Employing a numerical scheme for the assignment of 
quantitative scores
To address the above-described limitations of the qualita-
tive measure, we introduced weighted internal scores to
each of the 14 criteria, as presented in Table 2. The actual
data for determination of the internal scores was extracted
from the relevant experimental studies. The internal score
scaling was based on the number of sources and/or the
intensity of the results which contributed to the particular
criterion. Accordingly, the maximal internal score was 2
for most criteria, except for Macrophage and Vaccine,
which were up-weighted due to their significance/rele-
vance to vaccine development, by giving a maximal inter-
nal score of 3. These scoring rules were also useful for the
final ranking among high scoring genes. The final quanti-
tative score calculated for each ORF product, is the total of
the internal scores assigned in each of the 14 criteria for a
particular ORF product. As expected, the quantitative
scores allowed dissecting the large groups of equally qual-
itatively scored antigens, and ranking further the candi-
dates. These scores can be used as a tool for further
trimming down the number of vaccine candidates, and
selecting for the top-hit targets. This process generated a
list of 55 antigens with a qualitative score value of 6 and
above. Of this list, 10 antigens were predicted to harbor
more than 5 membrane-spanning domains (Rv0286,
Rv0290, Rv0450c, Rv0754, Rv1196, Rv1348, Rv1736c,
Rv1737c, Rv1997, Rv2123). Although potentially valua-
ble vaccine targets, these antigens were removed from the
list due to the potential technical problems which may
occur during cloning and production of such recom-
binant proteins. Consequently, a list of 45 top ranking
antigens is provided (Table 3). In this list, the antigens are
sorted by their qualitative score and consecutively – by
their quantitative score. According to this type of ranking,
the antigens are clustered into groups, by limiting both
the qualitative and the quantitative lower value scores in
a certain group. For instance, Group I of antigens includes
candidates having a qualitative score of 8 and above, pro-
vided that the quantitative score is not lower than 12.
According to such an approach for ranking, the antigens
were delineated into three groups: the first includes the 12
top best-hit antigens both in terms of qualitative and
quantitative scores and the following second and third
groups comprise of 20 and 13 antigens, respectively
(Table 3). There are other modes of sorting which could
be considered as well, giving more weight to the quantita-
tive score vs. the qualitative score and vice versa. It should
be mentioned though, that using these different ranking
approaches had marginal consequences on the grouping,
affecting mainly those antigens at the edges of each of the
groups.
Functional categories of the selected genes
According to the revised gene annotation and the accumu-
lating data from the literature, the 189 selected antigens
were assigned a functional category (listed in Additional
file 1: List of 189 selected antigens) following the classifi-
cation implemented previously for the Mtb complete
genome sequence by Cole and coworkers (and re-anno-
tated by Camus and co-workers, [26,51]). Figure 2
presents a graphic view of the gene distribution according
to the functional categories, in the repertoire of the 189
selected genes. When compared to their fraction in the
whole genome [51], it appears that the Conserved hypo-
thetical proteins category is under-represented in the list
of 189 selected antigens, while the Lipid metabolism and
Virulence, detoxification and adaptation categories are
over-represented in the list of 189 selected antigens. To
note, this higher fraction is a bona fide observation, and
not a result of antigens which were re-assigned to a new
functional category following the updated annotation.
(1) Conserved hypothetical proteins
In the complete genome, 33% of the genes were assigned
a functional category of either Conserved hypothetical
proteins or Proteins of unknown function [51]. The pro-
portion of this class of antigens is reduced to 14% in the
list of 189 candidates presented in this study, resulting in
27 proteins for which the function remains unknown.
This observation is evidently the consequence of the revi-
sion of annotation carried out in this study for the 189
selected genes, a process which, as detailed above, was
based on cross-matching the in silico analysis against
updated databases and accumulating data from the litera-
ture. The revised annotation contributed mostly to anti-
gens which were consequently assigned as Intermediary
metabolism and respiration (~75% of the re-annotated
antigens). For example, of the 69 antigens which were re-
annotated in this study, proteins Rv1461 and Rv1462,
originally marked as hypothetical proteins, were found
(both by domain analysis and literature search) to be part
of the SUF machinery (mycobacterial system of [Fe-S]
cluster assembly) identified by Huet and coworkers
[145,146]. Likewise, most Usp proteins selected in this
study were annotated as hypothetical proteins, and theBMC Medical Genomics 2008, 1:18 http://www.biomedcentral.com/1755-8794/1/18
Page 10 of 25
(page number not for citation purposes)
functional assignment permitted to associate them with
the stress protein family (see below). The potential contri-
bution of ORFs with unassigned function to immuno-
genicity and vaccine is clearly demonstrated by the fact
that of the 27 proteins in this category, 22% (6 antigens)
are included in the list of 45 top-hits antigens (Table 3).
All the six antigens are DosR regulon antigens and are also
among the top-best T-cell antigens determined in this
study (see below).
(2) Lipid metabolism
Accumulating information suggests that fatty acids, rather
than carbohydrates, constitute the dominant carbon sub-
strate utilized by Mtb during infection [147]. Bacteria iso-
lated from lungs of infected mice were shown to oxidize
preferentially fatty acids [148]. Moreover, the genes
encoding fatty acid catabolic β-oxidation cycle enzymes
are extensively duplicated in the genome [26,51]. In view
of the nature of the dataset and the sources of information
mostly related to aspects of the intracellular lifestyle of the
bacilli and its survival, it is not surprising that the fraction
of antigens related to lipid metabolism is as high as 16%
(30 out of the 189 selected), compared to 6% (~240 anti-
gens out of 3989) in the whole genome (p-value = 1.02 ×
10-4) (Figure 2). Among the proteins involved in these
processes, are many proposed vaccine candidates and
drug targets. Several antigens have also shown promising
cellular and humoral immune responses. Four out of the
30 proteins selected are among the 45 top-hit antigens.
Basically, lipid metabolism can be divided into two main
divisions:
(I) Lipid biosynthesis, modification and degradation
In this division are included 22 out of the 30 proteins in
the category. Of the two discrete types of enzymes
involved in fatty acid biosynthesis in bacteria, the type I
and type II fatty acid synthases (FAS-I and FAS-II, respec-
tively), condensing enzymes that catalyze the formation
of carbon-carbon bonds, have received considerable inter-
est, two of which are included in the 189 selected genes:
kasA  and  kasB  (Rv2245 and Rv2246, respectively)
[26,149]. The kasA-kasB  operon (β-ketoacyl-ACP-syn-
thases) is necessary for synthesis of fatty acids, mycolic
acid and polyketides, by initiating the subsequent rounds
of acyl extension [150,151]. Few antigens selected in this
study are related to biosynthesis of polyketides: a pks-
associated protein (papA3, Rv1182) and a putative regu-
lator of pks expression (annotated originally as a hypo-
thetical protein, Rv1186c), the mycobactin biosynthesis
operon (Rv2377c–Rv2386c, discussed below, in the sec-
tion related to iron acquisition) as well as the polyketide
non-peptide synthase (Rv0101c). Disruption of Rv0101
interrupts the virulence-related, cell wall constituent pico-
thocerol dimycocereosate (DIM) biosynthesis, producing
an avirulent strain with vaccine properties comparable to
BCG [152]. The protein fadD26 (Rv2930) included in our
selection, is a necessary part of the operon for biosynthesis
of DIM [153], and its mutant is attenuated in mice and
induces better protection than BCG when administered
sc. [154]. The mutant is also associated with early attenu-
ation of growth in macrophages [134]. Proteins involved
in lipid modification include the Acyl-acyl carrier protein
(ACP) desaturases, which convert saturated to unsatu-
rated fatty acids. Three desaturases, desA1-A3, part of a
multi-protein iron-enzyme complex (Rv0824c, Rv1094
and Rv3229c) were selected in this study. As for lipid deg-
radation: fatty acid degradation genes are extensively
duplicated in the genome (e.g. 36 paralogs capable of per-
forming the first step, [26]), of which 6 were selected in
this study (Rv0243, Rv3546, Rv2590, Rv3515c, Rv3139,
Rv3140). Five proteins that are functionally related to
lipid degradation are listed under either Intermediary
metabolism and respiration (Rv1130 (prpD), Rv1131
(gltA1, citrate synthase), Rv0467 (icl) and Rv0211 (pckA))
or in PE and PPE proteins (Rv1169c). Rv1130, annotated
originally as conserved hypothetical protein, is a homolog
of S. typhimurium prpD and mmge – genes involved in β-
oxidation of fatty acids, upregulated in macrophages [62],
and essential for ex vivo intracellular growth. Rv0467 a
member of the glyoxalate pathway, was one of the first
genes reported to contribute to persistence [155-157].
Rv0211 encodes a gluconeogenetic rate-limiting enzyme
– suggesting that fatty acids are in part converted into sug-
ars via gluconeogenesis. In addition, Rv1169c (PE11),
classified as a PPE and PPE protein, is one of numerous
lipases which may be involved in host cell wall degrada-
tion, shows homology to triacylglycerol lipase, a paralog
of which has been recently shown to be immunogenic
[158,159].
(II) Lipid cell wall composition
Mycolic acids are high molecular weight α-alkyl,  β-
hydroxy fatty acids crucial for the architecture and perme-
ability of the mycobacterial cell envelope. Free-standing
lipids, lipoglycans, and proteins also intercalate within
this complex. This layer is covered by a capsule consisting
of polysaccharides, proteins and lipids. The consequences
of these structural unique features are an extremely sturdy
and impermeable cell envelope [151,160-162]. Mycolic
acids containing glycolipids, in particular the prominent
trehalose-6,6'-dimycolate (TDM), stimulate cellular and
humoral immune response and granuloma formation
[163]. Several gene products involved in mycolic acid bio-
synthesis and modification were selected in this study.
Mycolyl transferases (Ag85 complex) are a family of pro-
teins responsible for synthesis of cell-wall components –
such as cord factor biosynthesis in Mtb (a dominant
immunogenic and immunomodulatory structure neces-
sary for maintenance of cell-wall integrity/virulence and
an inhibitor of phagosome-lysozome fusion, [163,164]).BMC Medical Genomics 2008, 1:18 http://www.biomedcentral.com/1755-8794/1/18
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Mycolyl transferases are also termed: fibronectin binding
proteins, and have been shown to be involved in host
entry. Two representatives are included in our selection,
Ag85A (Rv3804) and Ag85B (Rv1886), both classical,
well documented B-cell and T-cell immunogens and vac-
cine candidates. Another protein selected herein is cmA2
(Rv0503c), which plays a role in the modulation of the
host immune response, by modifying the cord factor,
hence forming a lipid molecule which suppress inflam-
mation [165,166]. Finally, antigen Rv3130c, originally
annotated as a hypothetical protein is actually tgs – mem-
ber of a novel class of diacylglycerol acetyltransferases
responsible for accumulation of triacylglycerol in Mtb as
it enters a dormancy-like state in culture [167]. This anti-
gen is constitutively over expressed in the epidemic Mtb of
Table 2: Numerical internal scores.
Criterion Internal score Maximal score
Macrophage (0) no evidence 3
(1) significant evidence from one source
(2) significant evidence from two sources
(3) significant evidence from > two sources + high value
MprAB (0) no evidence 2
(1) <3.0 fold expression
(2) >3.0 fold expression
Hypoxia (0) no evidence 2
(1) 1 evidence
(2) >1 evidence, high values
Reactivation (0) no evidence 2
(1) evidence from one source
(2) evidence from two sources
Dormancy (0) no evidence 2
(1) low values
(2) high values
Lung (0) no evidence 2
(1) evidence from one source
(2) multiple evidences (or Rachman/Jain source)
acr-coregulated (0) no evidence 2
(2) up regulated
Secreted (0) no evidence 2
(1) secreted
(2) secreted+virulence-related function
B-cell immunogen (0) no evidence 2
(1) evidence from one source
(2) multiple evidences
Iron regulated (0) no evidence 2
(1) low values
(2) high values
Cell wall (0) not related 2
(1) general association (without tm)
(2) virulence-related function
Vaccine (0) no evidence 3
(1) DNA/protein immunization, immune respone but no protection
(2) part of a multivalent construct, protection
(3) DNA/protein vaccine protection
Repeats (0) no repeats 2
(1) repeats only
(2) repeats + virulence-related function
T-cell
Experimental (0) no evidence 2
(1) evidence from one source
(2) multiple different evidences
Predictions (0) 0< #supertypes <6 2
(1) 6 < #supertypes <10
(2) 10<#supertypes <12BMC Medical Genomics 2008, 1:18 http://www.biomedcentral.com/1755-8794/1/18
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Table 3: Top-ranking 45 antigens (sorted by quantitative and qualitative scores).
Group Rv # Gene (a) Length 
(aa)
Annotation (a) Qual 
Total
Quant 
Total
I Rv1738 94 hypothetical protein 9 14
Rv2450c rpfE 172 probable resuscitation-promoting factor rpfE [transglycosylase] 9 14
Rv2623 TB31.7 297 hypothetical protein TB31.7 [universal stress protein] 9 14
Rv1009 rpfB 362 possible resuscitation-promoting factor rpfB [transglycosylase, C5 
adhesion domain]
91 3
Rv0867c rpfA 407 possible conserved trans-membrane protein [transglycosylase, rpfA] 9 12
Rv2031c acr (α-
crystallin)
144 heat-shock protein HspX (alpha-crystallin homolog) 14 kDa antigen 
Hsp16.3
81 4
Rv1886c fbpB (Ag85B) 325 secreted antigen 85-B FBPB (85-B) (mycolyl-transferase 85B) 8 14
Rv0288 esxH (TB10.4) 96 Low Mw protein antigen 7 esxH (10 kDa antigen) CFP-7, TB10.4) 8 13
Rv2032 acg 331 conserved hypothetical protein Acg [nitroreductase] 8 13
Rv2626c 143 hypothetical protein [CBS pair – binding/regulation, euk] 8 13
Rv3873 PPE68 368 PPE family protein [PPE68, RD1 T/B immunogen] 8 13
Rv2005c 295 hypothetical protein [USP-like] 8 12
Rv3127 344 hypothetical protein [possible nitroreductase] 8 12
II Rv1733c 210 probable conserved trans-membrane protein 8 11
Rv1996 317 hypothetical protein [USP] 8 10
Rv2389c rpfD 154 probable resuscitation-promoting factor rpfD [transglycosylase] 8 10
Rv0685 Tuf 396 elongation factor Tu [iron-regulated] 8 9
Rv2628 120 hypothetical protein 8 9
Rv1980c mpb64 228 immunogenic protein MPT64 7 13
Rv3804c fbpA (Ag85A) 338 secreted antigen 85-A FBPA (85-A) (mycolyl-transferase 85A) 7 13
Rv0079 273 hypothetical protein 7 11
Rv3130c [tgs1] 463 hypothetical protein [diacylglycerol acyltransferase] 7 11
Rv3131 [bfnB] 332 hypothetical protein [possible nitroreductase NfnB] 7 11
Rv0824c desA1 389 probable acyl [-acyl-carrier-desaturase desA1] 7 10
Rv1908c katG 740 catalase-peroxidase-peroxinitritase-T katG 7 10
Rv1174c [sak5] 110 Low Mw T-cell antigen TB8.4 [secretion antigen SA5K] 7 9
Rv1349 [irtB] 579 probable drugs transport ATP-binding protein ABC transporter [ATM1 
ABC siderophore-iron transporter]
79
Rv1813c 143 hypothetical protein 7 9
Rv2006 otsB1 1327 probable trehalose-6-phosphate phosphatase OTSB1 7 9
Rv2029c pfkB 339 possible phosphofructokinase (pfkB) 7 9
Rv2627c 413 hypothetical protein 7 9
Rv2780 ald 371 secreted L-alanine dehydrogenase ald (40 kDa antigen, TB43) 7 9
III Rv1884c rpfC 176 probable resuscitation-promoting factor rpfC [transglycosylase] 7 8
Rv2620c 141 probable conserved transmembrane protein 7 8
Rv2744c 35kd-Ag 
[pspA]
270 conserved 35 kDa Alanine-rich protein [phage-shock protein IM30] 7 8
Rv3875 esxA 95 6 kDA early secretory antigenic target ESXA (ESAT-6) 6 11
Rv1926c mpt63 159 immunogenic protein MPT63 (16 kDa immunoprotective extracellular 
protein)
61 0
Rv2030c 681 hypothetical protein [putative esterase/transferase] 6 10
Rv3132c devs 578 two component sensor histidine kinase DEVS 6 10
Rv3347c PPE55 3157 PPE family protein (PE55) [8 copies pentapeptide repeats] 6 10
Rv0467 icl 428 isocitrate lyase(icl) [AceA] 6 9
Rv1130 [prpD] 526 hypothetical protein [2 methyl-citrate dehydratase] 6 9
Rv1169c PE11 100 PE family protein (PE11) [triacyl glycerole lipase] 6 9
Rv1793 esxN 94 putative ESAT-6-like protein ESXN (ESAT-6-like protein 5) 6 9
Rv2629 374 hypothetical protein [peptide release factor erF1] 6 9
The antigens are sorted by the qualitative score (Qual Total) and subsequently by the quantitative score (Quant Total) (see text). Group I includes 
all antigens with a qualitative score 8 and above, provided that the quantitative score is not lower than 12. The rest of the antigens having a 
qualitative score of 8 and those having a qualitative score of 7 and a quantitative score not lower than 9 were clustered into Group II. Group III 
included antigens with qualitative scores of 7 (and quantitative score of 8) and 6 (with a quantitative scores 9 and up). (a) The Gene name and 
annotation are based on the data deposited at the NCBI, [GenBank: AL123456]. In square brackets: updated gene name and/or annotation, resulting 
from the analyses conducted in this study.BMC Medical Genomics 2008, 1:18 http://www.biomedcentral.com/1755-8794/1/18
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the W-Beijing lineage strain in comparison to non W-Bei-
jing strains [168].
(3). Virulence, detoxification, adaptation
Inspection of Figure 2 reveals that antigens included in
this functional category are enriched in the list of 189 anti-
gens: 12% (23 antigens) as compared to only 2% (~80
antigens out of 3989) in the whole genome (p-value = 1.2
× 10-5). This is a consequence of the emphasis given to
selection of antigens related to the pathogenesis traits. Of
the 23 antigens, 6 are included in the list of 45 top-hit
antigens. A total of 11 candidates in this category are stress
proteins, belonging to the Universal stress protein (Usp)
and the Heat shock protein (Hsp) superfamilies. The Usps
encompass a conserved group of proteins involved in
stress resistance, adaptation to energy deficiency, cell
motility and adhesion [169]. The paradigm usp gene, uspA
of Escherichia coli is transcriptionally activated by a large
variety of stresses and is one of the most abundant pro-
teins in growth arrested cells [170]. In our analysis, 6 out
of the eight usp  genes in the Mtb genome [171] were
selected as vaccine candidates: Rv1636 (single Usp
domain), Rv2028c, Rv3134c (a Usp domain followed by
a typical C-terminal domain) and Rv1996, Rv2005c, and
Rv2623 (harboring two Usp domains, and possessing a
conserved ATP-binding motif and no signal sequence).
Rv2623, Rv2005c, Rv2028c, and Rv3134c have been
shown to be up-regulated under hypoxia [67], suggesting
that they play a role in adaptation and survival of myco-
bacteria during growth arrest caused by oxygen limitation.
The Hsp subfamily includes the extensively studied M.
tuberculosis α-crystallin (acr) family-related proteins. The
Mtb genome harbors 2 paralogs belonging to the acr fam-
ily (hsp20/acr, Rv2031c and acr2, Rv0251). Rv2031c is
regulated by the two-component regulatory system (DosR
regulon), as detailed above, and is a latency stage disease
marker [111]. While acr is induced by hypoxia or nitric
oxide, acr2 is reported to be the protein most up-regulated
under heat-shock as well as expressed under nitric oxide
or during uptake by macrophages. Heat shock proteins
assist in Mtb survival but also provide a signal to the
immune response. acr2 has been shown to elicit a strong
Distribution of Mtb genes according to functional categories Figure 2
Distribution of Mtb genes according to functional categories. The categories are adapted from Cole and his cowork-
ers [26]. For practical reasons, the categories of "Conserved hypothetical proteins" and "Proteins of unknown function" were 
joined (category (III) in the Figure). Category (VI) encompasses the functional classes which were either less abundant or non 
existent in the list of 189 antigens selected herein. The percentage of genes in each of the functional categories is provided, as 
retrieved from Camus and his coworkers for the whole genome (A) [51], and calculated for this study 189 selected antigens 
(B) and 45 top-ranking antigens (C).
(I) Intermediary metabolism and respiration
(II) Cell-wall and cell processes
(III) Hypothetical+unknown
(IV) Lipid metabolism
(V) Virulence, detoxification, adaptation
(VI) Regulatory proteins; Insertion sequences and phages; Information pathway
(VII) PE and PPE proteins
B. 189 Selected  Antigens A. Whole Genome C. 45 Top-Hit  AntigensBMC Medical Genomics 2008, 1:18 http://www.biomedcentral.com/1755-8794/1/18
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cellular response in cattle during early primary infection
and thus has been suggested as a candidate for stage spe-
cific TB vaccine [172]. This protein is also tightly regulated
by MprAB [173]. While analyzing immunogenicity of
eight dormancy-regulon encoded proteins as DNA vac-
cines in a mouse model, Roupie and coworkers [25] have
shown that Rv2031c induces the strongest Th1 response,
and that mice persistently infected with Mtb developed an
immune response against this gene. Both acr  and acr2
have been documented as contributing to persistence
[174]. Other Hsp proteins selected by this study are the
endopeptidase Rv0384c (ClpB), Rv0350 – dnaK-Hsp70,
and Rv0351-grpE (Hsp-70 cofactor), which are up-regu-
lated in anaerobic stationary phase in M. smegmatis.
PBMCs from TB patients and vaccinated individuals have
been recently checked for cytokine profiles in response to
DnaK [98]. To note, 4 out of the 6 candidates in the Viru-
lence, detoxification and adaptation category included in
the list of 45 top-ranking, are stress proteins (Rv1996,
Rv2005c, Rv2031c and Rv2623).
Antigens Rv2006 and Rv3372 are part of the OstAB path-
way, which was found to be essential for Mtb growth and
virulence in mice [175,176]. This pathway involves the
generation of Trehalose, a major cell-wall constituent of
glycolipids. Rv3372 was recently reported to be an immu-
nodominant antigen, inducing both humoral and cellular
immune response. The enzyme was also recognized by
patient's sera and BCG vaccinated donors; however no
protection data was mentioned [177]. Rv1908c (KatG, a
catalase/peroxidase/peroxinitritase) has been mostly
studied in the context of resistance to isoniazid as well as
in development and detection of MDR strains [178,179].
Intra-macrophage expression of katG is associated with
growth and persistence of Mtb in mice and guinea pigs
[180]; immunization with a multivalent combination
DNA vaccine (containing the ESAT-6, MPT-64, MPT-63,
and KatG) generated antigen-specific cell-mediated and
humoral responses and elicited a strong protective
response relative to BCG [122].
Another virulence-related family of proteins is Nlpc_p60,
which belongs to the Firmicutes CHAP-related super-
family, consisting mainly of peptidoglycan hydrolases
involved in cell separation. Recent evidences attribute a γ-
glutamate-meso-diaminopimelate muropeptidase activity
to Nlpc_p60 proteins [181]. Two members of this family,
located in a single operon, are present in the Mtb genome,
both selected herein: Rv1477 and Rv1478. It has been
shown the M. marinum orthologs (iipA and iipB) are essen-
tial for virulence in-vivo, invasion and intra-cellular per-
sistence in macrophages [182]. Moreover, it has been
specified that the N-terminal sequence of Rv1477 is
required for full virulence in vivo and in macrophages. In
a recent study, Rv1477 was identified as an RpfB interact-
ing protein (resuscitation promoting factor B, an impor-
tant cell-wall hydrolase, see below), suggesting a role in
cell division during reactivation/resuscitation [183].
Unlike the three functional categories described above, for
which a major difference exists between their relative dis-
tribution in the list of 189 selected antigens as compared
to that in the whole genome, a similar fractional distribu-
tion is observed in both lists with respect to the functional
categories: Intermediary metabolism and respiration and
the Cell wall and cell processes. The former includes 46
antigens, and obviously a thorough discussion of each of
these antigens is beyond the scope of this paper, yet we
would like to address three major clusters:
Iron acquisition
Iron acquisition-related gene products identified as candi-
dates in this study, include a total of 16 antigens, 7 of
which are classified as Intermediary metabolism and res-
piration proteins and are part of the SUF (mobilization of
sulfur) machinery or iron storage proteins, while the
remainder are siderophores-related proteins, classified
either under the categories of Lipid metabolism or in the
Cell wall and cell processes (ABC transporters, see below):
(1) Siderophores: Mtb synthesize siderophores of the sal-
icylate group, named mycobactins [90,184,185]. These
are produced exclusively under iron limitation both as a
membrane bound as well as soluble forms. The mbt-1
locus contains the siderophore core biosynthetic appara-
tus [90,91], members of which were selected by this study
the non-ribosomal peptide synthetases MbtB and MbtE
(Rv2383c, Rv2380c) two polyketide synthetases MbtD
and MbtC (Rv2381c and Rv2382c), an isochorismate syn-
thase (MbtI, Rv2386c), a hydroxylase (MbtG, Rv2378c)
and the conserved protein MbtH (Rv2377c). MbtB
mutants impaired in siderophore biosynthesis are unable
to replicate in infected macrophages [186]. The mbt-1
locus genes were included in the Lipid metabolism cate-
gory, given that these are polyketide biosynthesis compo-
nents. Also selected as part of the iron acquisition
apparatus are the ABC transporters IrtA and IrtB (Rv1348
and Rv1349, respectively) which actively transport the
iron-siderophore complex. Inactivation of these genes
drastically affects the ability of Mtb to replicate. irtAB
mutant is attenuated for survival in infected macrophages
and lungs of infected mice [187]; (2) The SUF (mobiliza-
tion of sulfur) machinery: A locus of seven proteins was
functionally identified by Huet and coworkers [145,146]
as harboring the Mtb suf machinery – an exclusive myco-
bacterial system of [Fe-S] cluster assembly, probably
essential for survival via its implication in bacterial resist-
ance to low iron limitation and oxidative stress. The sys-
tem is required for maturation of physiologically
important metalloproteins. Sassetti and coworkers [61]
defined this operon as necessary for in-vitro mycobacterialBMC Medical Genomics 2008, 1:18 http://www.biomedcentral.com/1755-8794/1/18
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growth. Of this locus, our selection disclosed 5 compo-
nents (Rv1461 (SufB), Rv1462 (SufD), Rv1464 (SufS),
Rv1465 (NifU) and Rv1466. Rv1466 presents no homol-
ogy with any documented suf gene but probably acts as a
predicted metal-sulfur biosynthesis enzyme. Consistently,
Rv1461 to Rv1466 are over-expressed in Mtb grown on
low iron [94]. Moreover Rv1460, Rv1463 and Rv1464
have been described as stress response genes transcrip-
tionally up-regulated in anaerobic stationary phase in M.
smegmatis; (3) Iron storage proteins – bacterioferritin: Fer-
ritins constitute the major non-heme iron storage proteins
in animals, plants and microorganisms, playing an impor-
tant role in ferric iron homeostasis. The Mtb genome har-
bors 2 paralogs: bfrA (Rv1876) and bfrB (Rv3841) both
selected in this study. The bfrB antigen has been shown to
be abundant under hypoxic conditions [188], a dominant
T-cell antigen in infected mice [189] and antigenic in
human disease [190].
Of the 16 candidate genes related to iron acquisition, only
the two ABC transporters classified as Cell wall and cell
processes category, Rv1348 and Rv1349, received rela-
tively high score (qualitative scores of 7), yet the former
was not included in the list of 45 top-hit candidates,
because of a high number of transmembrane segments.
Nitroreductases
One of the activities induced in Mtb by hypoxia is the dis-
similatory reduction of nitrate to nitrite which serves as an
energy source as bacteria adapt to anaerobiosis [66,191].
Five nitroreductase-related proteins are included in the list
of the selected 189 antigens, 4 of which are classified
under Intermediary metabolism and respiration. The Mtb
genome contains 2 loci homologous to prokaryotic respi-
ratory NAR (nitrate reductase) genes [26]. The first-
narGHJI is not represented in the list of 189 genes, while
the second locus contains two antigens, both selected in
this study: nitrate reductase narX (Rv1736), exhibiting
strong similarity to the narGHJI cluster (yet probably inac-
tive as a classical reductase [192]) and narK2 – a nitrite
extrusion protein (Rv1737c), a member of the devR regu-
lon (acting as a redox sensor [191] and an hypoxia
induced antigen [67]). Three other selected ORF products,
listed as putative nitroreductases, are part of a family of 8
unusual nitroreductases identified by Purkayashta and
coworkers [79]: The hypoxia-induced acg (Rv2032, neces-
sary for survival) and two paralogs (Rv3127 and
Rv3131c), all harboring parts of the 5 nitroreductase
order-conserved motifs identified [79]. Interestingly, of
the five nitroreductase-related antigens selected, three
(Rv2032, Rv3127 and Rv3131c) are included in the list of
45 top-hits.
Proteases
Although many proteases are documented as virulence
factors in other pathogenic bacteria, little information is
available regarding their role in mycobacteria pathogenesis.
The Mtb genome harbors ~60 putative proteases [48], of
which only 7 are included in the 189 list (all except one
are classified under Intermediary metabolism and respira-
tion). Among these are proteases being evaluated in vac-
cine studies: the classical Rv0125, a DegQ-like serine
protease (HtrA-family), a construct of which with
Rv1196c demonstrated protective efficacy equal to BCG in
diverse animal models [135,193] and; the zinc-metallo-
protease Rv0198c (pepO, an M13 peptidase resembling
eukaryotic neprilysin [194]), which was evaluated as a
vaccine candidate by Vipond and coworkers [96,97].
Rv2625c, originally annotated as a conserved transmem-
brane Ala and Leu-rich protein, is probably a zinc protease
and part of the DosR regulon. Rv2869c is a homolog of
the eukaryotic site two protease (S2P) controlling mem-
brane compositions. In Mtb it has been recently found
that the enzyme controls cell envelope composition, in-
vivo growth and persistence [195]. Knockout mutants of
Rv2869c exhibited reduced expression of genes related to
lipid biosynthetic and degrading genes, including the
resuscitation factor rpfC. Rv2224c was identified as a puta-
tive virulence gene by high throughput techniques and
attenuation studies [61,76], and shown to be preferen-
tially expressed in human macrophages and up-regulated
after the onset of starvation. Similar to Rv2869c, Rv2224c
may modify envelope composition or, alternatively,
hydrolyze fatty acyl esters with mycobactericidal activity
[196]. Another selected protease gene is the HslV protease
Rv2110c (prcB, proteosome β-subunit), a core component
of the proteosome, known to play a critical role in bacte-
rial stress defense. None of the proteases selected in this
study are represented in the list of 45 top-hits.
It is well established, that the characteristic mycobacterial
cell envelope is a dominant feature of the biology of M.
tuberculosis  and other mycobacterial pathogens (as
described above under lipid synthesis). Indeed, the sec-
ond largest category which has a similar representation in
the list of 189 selected antigens as in the whole genome,
is the Cell wall and cell processes (a total of 38 antigens
selected in this study). Most strikingly, 37% of the anti-
gens under this functional category are included in the list
of 45 top-hits candidates. This group contains three clus-
ters of key antigens: the ESX secretion system, the resusci-
tation antigens and lipoproteins
The Esat-6 system (ESX)
The ESX is one of the 4 secretion systems which have been
identified so far in Mycobacterium tuberculosis, and consti-
tutes a major determinant in mycobacterial pathogenesis
and immunogenicity. ESX-derived antigens have beenBMC Medical Genomics 2008, 1:18 http://www.biomedcentral.com/1755-8794/1/18
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described as immunogens in infected cattle [124,197],
dominant early-phase T-cell antigens
[102,106,119,127,136,142,198], putative subunit vac-
cine candidates [85,107,120], as well as potentiators of
BCG vaccines [20]. These antigens have been also exten-
sively studied as promising immunodiagnostic markers
[84,85], and in mechanistic/regulatory studies ([199-201]
and references therein).
The complete genome of Mtb H37Rv harbors five ESX
copies (not necessarily identical, [202]). The ESX1 locus,
the most well studied, is located in the extended region of
difference 1 (extRD1) of the genome, and therefore absent
from all vaccine strains of M. bovis BCG. The products of
this system locus are suggested to modulate early events
during infection (e.g. [102,199-201] and references
therein) and involved in phenotypes as growth in macro-
phages, suppression of the macrophage inflammatory
and immune response, phagosome maturation arrest
[203] and virulence factor delivery. Sixteen ESX proteins
are represented in the 189 selected antigens (9 of these are
listed under the Cell wall and cell processes functional cat-
egory). These include the classical well documented anti-
gens: ESAT-6 (esxA, Rv3875) and 2 of its paralogs (the
well studied vaccine candidate Rv0288 (esxH) and
Rv1793 (esxN)), and CFP10 (esxB, Rv3874) and its para-
log (esxG, Rv0287). In addition, the following ATPases
were shown to be core components of the ESX system:
Rv3871, Rv0282, Rv0283, and Rv0284, Rv3876 as well as
the Ala-rich protein Rv3878 and Rv3879c, the transport-
ers Rv0289 and Rv0290 and Rv0292, a transmembrane
protein. Rv3616c (EspB) a recently identfied effector of
this secretion system, was selected herein as well. In total,
three ESX components (Rv0288, Rv1793 and Rv3875) are
part of the 45 top-hit antigens.
Resuscitation promoting factors (Rpfs)
The Rpfs, secreted or membrane-anchored peptidoglycan/
glycosyl hydrolases [204,205] were originally identified in
Micrococcus luteus, promoting the recovery of bacteria
from latency to a replicating phase [206]. In a later study
the presence of similar autocrine growth factors in Mtb
was reported [123,207]. Five Mtb gene products encoding
Rpf homologs were identified (Rv0867c-rpfA, Rv1009-
rpfB, Rv1884c-rpfC, Rv2389c-rpfD  and Rv2450c-rpfE,
[55]) and documented to have resuscitation activity [70].
Two strains of Mtb in which three rpfs were deleted were
both attenuated in mice and did not reactivate in an in
vitro reactivation assay [208]. Also, s strain lacking rpfB
exhibited a delayed reactivation in a mouse dormancy
model and reduced mouse lung colonization [71]. The
Rpf proteins are secreted or membrane anchored, which
renders them candidates for recognition by the host
immune system. Affinity purified antibodies were shown
to inhibit bacterial growth in vitro and it has been sug-
gested that sequestration of Rpfs might also provide a
means to limit/prevent bacterial multiplication in vivo
[123,207]. When administered as subunit vaccines to
mice, 4 out of 5 Mtb Rpfs were found to be highly immu-
nogenic, eliciting both IgG1 and IgG2a responses (highest
for Rv2389), T-cell proliferation and cytokine production.
Vaccination of mice with RpfE (Rv2450c) results in signif-
icant protection against subsequent high-dose challenge
with a virulent strain (in survival times and bacterial mul-
tiplication in lungs and spleen) to levels comparable to
Ag85B and Esat-6 [88]. As mentioned, all the five known
resuscitation promoting factors are included in the 45
top-ranking hits; three of which (RpfE, RpfB and RpfA)
belong to the highest scoring group (GroupI, Table 3).
Lipoproteins
Lipoproteins are reported to affect both innate and adap-
tive immunity as well as bacterial in vivo growth and viru-
lence. Of 48 predicted lipoproteins in the Mtb genome
[209], 6 were selected in this study, and at least four are
directly relevant for vaccine design. The classical 19 kDA
antigen (Rv3763), is a well studied glycosylated lipopro-
tein acting as a phagocytosis stimulating adhesion [210]
factor through TLR2 signaling in the macrophage, thus
facilitating the bacilli persistence [209]. The lipoprotein
LprG (Rv1411c) required for growth in mice [211], is a B
and T-cell antigen [212], inducing protective T-cell
response within the lungs of infected mice sufficient for
early control of Mtb [140]. It is probably acting as a TLR-
2 ligand, inhibiting MHC class II antigen processing
[213,214]. In a more recent study, a fusion protein of
Rv1411c with ESAT-6 (where Rv1411c acts as a natural
adjuvant) was constructed, resulting in protection of mice
exposed to low dose aerosol challenge [214]. RpfB
(Rv1009), the only lipoprotein in the resuscitation factor
family, is another prominent representative described
above. In addition to these clusters of antigens, a promis-
ing cell wall antigen is the secreted T-cell antigen TB8.4
(Rv1174c). This protein, detected in human macrophages
and sputum of TB patients [215], affects growth of M.
bovis BCG in human macrophages and mice [216], prob-
ably via its role in both resistance to intracellular stress
and adaptation to hypoxia [217]. The Rv1174c knockout
mutants are attenuated in vivo and Rv1174c-derived pep-
tides were found to resuscitate one year old cultures [218].
Moreover, immunization with either plasmid DNA or the
Rv1174c recombinant protein induces a strong and pro-
tective T-cell response in mice [105].
Another functional cluster of proteins is the unique sur-
face-associated PE & PPE family, which encompasses
~4.5% of the Mtb genome [219-222] and a similar per-
centage in the 189 selected list (Figure. 2). The PE family
harbors a Pro-Glu motive at their N-terminus (positions 8
and 9 in a 110 residue long conserved domain). A sub-BMC Medical Genomics 2008, 1:18 http://www.biomedcentral.com/1755-8794/1/18
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group of the PE family is the PE-PGRS, where the PE
domain is followed by multiple tandem repeats of GGA or
GGN [223,224]. In the PPE family (ProProGlu N-terminal
motif, positions 7–9 in a 180 residue conserved domain)
the repeat domain is followed by a variable C-terminus
[221]. Originally members of this family were used as
strain differentiation markers [225]. PE/PPE genes are
widely present in pathogenic bacteria yet missing in non-
pathogenic species, and therefore are assumed to fulfill
important functions related to survival within different
environmental niches. Indeed, the first evidence came
from the observation that inactivation orthologs of the PE
gene product wag22 in M. marinum results in a replication
defect in macrophages and decreased survival in granulo-
mas [226]. Certain PE/PPE proteins play a role in immune
evasion and antigenic variation [26,219,223,227], others
are virulence related [224,226,228,229]. Evidence that at
least some PE_PGRS genes are antigens expressed during
infection in the host comes from serological studies.
Many of the PE/PPE proteins elicit strong immune
response [104,159,227,230-232]. Of the antigens selected
in this study, 10 belongs to the PE/PPE family (equivalent
to its fraction in the genome), of which three (Rv1169,
Rv3347c and Rv3873) are included in the top-ranking 45
antigens (see Additional file 1: List of 189 selected anti-
gens, and Table 3), most of them having particular indica-
tions as for their involvement in virulence and/or
immune response, as follows: PPE55 (Rv3347c) is recog-
nized by antibodies elicited during sub-clinical infections
of guinea-pigs and could be applied to the differentiation
between latent and incipient TB [233]. PPE protective sub-
unit (Rv3812) was recently identified as T-cell antigens
with vaccine potential [103]. Rv1169c elicits a strong but
differential B-cell response among different categories of
TB patients [234]. PPE68 (Rv3873) which is a member of
the RD1 region, was shown to act as both a T-cell and B
cell antigen in mice [106] and is also a constituent of the
ESX secretion system, as are the selected PE5 (Rv0285)
and PPE4 (Rv0286).
Distribution of immunopotent T-cell antigens
Inspection of the combined weighed scores of experimen-
tal data and predictions in the T-cell immunogenicity cat-
egory revealed that 29 antigens harbor the highest scores
in this category (a total quantitative score 3 or 4). Of
these, 70% (20 antigens) are included in the list of 45 top-
ranking candidates, where 4 of which are proteins of
unknown function. More strikingly, all 6 hypothetical
proteins in the list of the 45 top-ranking antigens are
immunopotent T-cell candidates (Rv0079, Rv1813c,
Rv2030c and Rv2627c are part of the 29 top best T-cell
antigens, while Rv1738 and Rv2628 are documented in
literature sources on individual antigens). The distribu-
tion of the remaining immunopotent T-cell antigens is
comparable, ~2–3 antigens per functional category. In
addition, among the 29 immunopotent antigens are also
included 3 out of the 8 antigens classified as Intermediary
metabolism and respiration in the list of 45 top hits, as
well as 2 of 4 Lipid metabolism categorized proteins, the
well documented classical Ag85A (Rv3804c) and Ag85B
(Rv1886c).
The 20 most immunopotent T-cell antigens included in
the list of 45 top-hit candidates, can also be examined
with respect to their distribution among different classes/
phases (as assigned for each ORF product, see Additional
file 1: List of 189 selected antigens). Out of the 20 anti-
gens, 11 are DosR regulon members (Rv0079, Rv1196,
Rv1813c, Rv2029c, Rv2030, Rv2031c, Rv2032, Rv2627c,
Rv3127, Rv3130c, Rv3132); 4 are classical vaccine anti-
gens (Rv1886c, Rv3804c, Rv1980c, Rv2875), one resusci-
tation antigen (Rv0867c), one putative reactivation
antigen (Rv0288) and 3 are listed under "others"
(Rv1908c – katG, Rv2780-ald, Rv3873-PPE68, an ESX1
component). Search for T-cell immune response data
originating from literature documentation on individual
antigens in the list of 189 selected genes identified at least
15 additional immunopotent candidates, 9 of which are
included in the top list of 45 antigens (the resuscitation
factors – Rv1009, Rv1884c, Rv2389, Rv2450; Rv1174c-a
low Mw T-cell antigen and the DosR regulon antigens –
Rv2006, Rv1738, Rv1733c, Rv2626c and Rv2628 studied
by Leyten and coworkers [24] & Roupie and coworkers
[25]). Interestingly, the most potent T-cell antigens, if esti-
mated solely on the in silico predictions of CTL binders
conducted herein are ~10 antigens harboring 80–200
epitopes recognized by all 12 supertypes (in decreasing
order Rv0101-nrp, Rv2380c-mbtI, Rv0284-ftsk, Rv2383c-
mbtB, Rv2006, Rv2590-fadD9, Rv3347c-PPE55, Rv0450c-
mmpL4, Rv1997-ctpF, and Rv1736c). It may be of interest
to evaluate experimentally these promising antigens for
their activity as T-cell antigens.
Conclusion
This study illustrates the process of screening the complete
Mtb genome, aiming at identifying and selecting potential
vaccine candidates. The screen was implemented to dis-
cern genes covering all phases of the infection, which
would, in turn, contribute either to construction of a
multi-stage vaccine or to the design of a subunit vaccine
supplemental to the BCG vaccine, solely directed to the
early-phase events of the infection. The strategy designed
for rational candidate selection was applied onto a knowl-
edge dataset which compiled numerous sources of rele-
vant published experimental information. The literature-
based dataset includes ~1200 antigens, for which evi-
dences on aspects relevant to vaccine and/or virulence
traits of the bacteria, existed (classified into 11 categories).
An initial reduction to a list of 344 antigens was con-
ducted, based on: (1) a preliminary total score calculatedBMC Medical Genomics 2008, 1:18 http://www.biomedcentral.com/1755-8794/1/18
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from the number of positive signs in the various catego-
ries, resulting in 143 antigens having a relatively high
score of 3–8; (2) a subsequent selection from the remain-
ing 201 antigens (scoring 1–2), by manual curation of
specific sources of information related either to vaccine or
pathogenesis; resulted in additional 46 antigens (interest-
ingly, only 4 of the 46: the classical Rv1908c, Rv1926c,
Rv1980c, and the ESAT protein Rv1793 were eventually
included among the final list of 45 top-hits antigens
(Table 3)). These filtering steps generated the list of 189
selected vaccine candidates, on which further extensive
bioinformatic and immunoinformatic analyses were con-
ducted. Of the 189 antigens in the list, only 34 were pre-
viously described in the literature as putative vaccine
candidates. These 34 known antigens represent over 80%
of the total number of such antigens listed in the previous
step of the selection process (see Figure. 1). Among these
34 antigens, at least 5 are under clinical trials (the classical
antigens: Ag85A (Rv3804c) and Ag85B (Rv1886c), ESAT-
6 (Rv3875); mtb72f: Rv0125 and Rv1196), 10 were used
in protective studies in animal models and 19 are candi-
dates eliciting a strong immune response.
Examination of the distribution of the 189 selected anti-
gens among whole genome-defined functional categories
(Additional file 1: List of 189 selected antigens) discloses
an enrichment of proteins related to lipid metabolism as
well as virulence and stress proteins, in comparison to
their fraction in the genome. Also, the in silico analyses
contributed to the updating of the annotation, resulting in
a dramatic decrease in the number of proteins of
unknown function in comparison to their fraction in the
whole genome. The comprehensive dataset was then
employed to rank the selected antigens, by applying a
ranking scheme based on the assignment of both qualita-
tive and quantitative scores to each of the antigens, in the
14 criteria employed. This ranking enabled to down select
a list of the best 45 candidates, denoted as top-hit antigens
(Table 3).
Inspection of the proposed list of 189 antigens provided
in Additional file 1: List of 189 selected antigens reveals
representatives of all classes/phases of the infection,
including early phase well-documented classical antigens
as well as 14 other early phase antigens. It is worth noting
that all five known resuscitation antigens (RpfA-E) are
included and furthermore, all 5 are among the 45 top-hit
antigens (Table 3). The DosR regulon comprises of ~50
genes [52,53,235] (1.3% of the genome), 36 of which are
represented in the list of 189 antigens, and 20 in the list of
45 top-ranking antigens (Additional file 1: List of 189
selected antigens and Table 3). Overall, an enrichment of
DosR-regulated and reactivation/resuscitation antigens is
observed in the list of 45 top-ranking antigens (74% as
compared to 36% in the list of 189 selected antigens).
This enrichment is obviously in part a consequence of the
criteria used for selection, which emphasize late stage
phases of the bacteria life cycle. In light of this observa-
tion, the result that early stage classical antigens (such as
Rv1886 (Ag85B), Rv3804 (Ag85A) and Rv0288 (esxH))
are found among the highest scoring candidates (GroupI
and GroupII of the top-ranking 45 antigens, Table 3), pro-
vides some validity to the methodology used in this study
to map antigens pertinent to all phases of the disease.
Murphy and coworkers [18] recently suggested a list of
118 putative dormancy drug targets; interestingly, 27 of
these overlap with our 189 selected candidates. Out of
these 27 antigens, 16 are part of the DosR regulon, and 11
are included in the list of 45 top-hit antigens. This extent
of overlap is a reflection of the facts that: (a) our datasets
are not identical; (b) in our analysis, considerable weight
was assigned to the immunogenic and virulence potential
of each ORF in the genome.
The list of top-ranking 45 antigens (Table 3) could there-
fore provide a platform for choosing combinations of rep-
resentatives from the late-stage antigens, which, together
with the classical antigens, may contribute to an improved
protection as compared to current vaccines based on the
early-phase directed BCG. Inclusion of DosR antigens in a
future vaccine may be essential in view of the apparent
limited immune response induced by the BCG to the
DosR regulon proteins, indicating that the vaccine strain
probably does not express these late stage antigens [118]
moreover the DosR regulon was shown to be constitu-
tively expressed in the Beijing epidemic strain [168], fur-
ther emphasizing the relevance of these late stage
proteins.
Guided by the analysis described in this study, and based
on the list of 45 top-ranking antigens (Table 3), we have
recently generated a novel rBCG vaccine denoted AERAS-
407, which allows over expression of the following
selected antigens from this list: (1) the classical antigens
Ag85A and Ag85B; (2) DosR regulon genes, the expres-
sion of which was induced via overexpression of dosR; (3)
the resuscitation antigens Rv0867c, Rv1884c, and
Rv2389c. In addition the AERAS-407 vaccine includes the
reactivation antigen Rv3407 [95]. This novel rBCG vac-
cine candidate has been produced and is currently under
experimental evaluation.
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